Masao Harada
About
Masao Harada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology.
According to data from OpenAlex, Masao Harada has authored 70 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 41 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Masao Harada's work include Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (24 papers) and Cancer therapeutics and mechanisms (12 papers). Masao Harada is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Lung Cancer Research Studies (24 papers) and Cancer therapeutics and mechanisms (12 papers). Masao Harada collaborates with scholars based in Japan, United States and India. Masao Harada's co-authors include Akira Inoue, Makoto Maemondo, Hiroshi Isobe, Hirotoshi Dosaka‐Akita, Kazuhiko Nakagawa, Tomohide Tamura, Nobuyuki Yamamoto, Takashi Seto, Ichiro Kinoshita and Yoshikazu Kawakami and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and The Lancet Oncology.
In The Last Decade
Masao Harada
64 papers receiving 2.4k citations
Hit Papers
Peers
Masao Harada
Katsuhiro Masago Japan
Alejandro Navarro Spain
G. Robinet France
Motoko Tachihara Japan
Maximilian J. Hochmair Austria
Panos Fidias United States
Giulia Pasello Italy
Francesco Facchinetti Italy
Saiama N. Waqar United States
See Phan United States
Citations per year, relative to Masao Harada Masao Harada (= 1×)
peers
Katsuhiro Masago
Countries citing papers authored by Masao Harada
Since
Specialization
Citations
This map shows the geographic impact of Masao Harada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Masao Harada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Masao Harada more than expected).
Fields of papers citing papers by Masao Harada
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Masao Harada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Masao Harada. The network helps show where Masao Harada may publish in the future.
Co-authorship network of co-authors of Masao Harada
This figure shows the co-authorship network connecting the top 25 collaborators of Masao Harada. A scholar is included among the top collaborators of Masao Harada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Masao Harada. Masao Harada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Nakamura, Atsushi, Masao Harada, Kana Watanabe, et al.. (2022). Phase II study of S-1 and irinotecan combination therapy in EGFR-mutated non-small cell lung cancer resistant to epidermal growth factor receptor tyrosine kinase inhibitor: North Japan Lung Cancer Study Group Trial 0804 (NJLCG0804). Medical Oncology. 39(11). 163–163.
2.
Fukumoto, Shinichi, Satoshi Oizumi, Masao Harada, et al.. (2020). A randomized phase II trial of cisplatin plus gemcitabine versus carboplatin plus gemcitabine in patients with completely resected non-small cell lung cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT0703). Cancer Chemotherapy and Pharmacology. 86(1). 117–127.
3.
Atagi, Shinji, Junki Mizusawa, Satoshi Ishikura, et al.. (2018). Chemoradiotherapy in Elderly Patients With Non–Small-Cell Lung Cancer: Long-Term Follow-Up of a Randomized Trial (JCOG0301). Clinical Lung Cancer. 19(5). e619–e627.
4.
Morikawa, Naoto, Akira Inoue, Shunichi Sugawara, et al.. (2017). Randomized phase II study of carboplatin plus irinotecan versus carboplatin plus amrubicin in patients with chemo-naïve extensive-stage small-cell lung cancer: North Japan Lung Cancer Study Group (NJLCG) 0901. Lung Cancer. 111. 38–42.
5.
Hirata, Kenji, et al.. (2016). Reproducibility and uptake time dependency of volume-based parameters on FDG-PET for lung cancer. BMC Cancer. 16(1). 576–576.
6.
Fukuhara, Tatsuro, Makoto Maemondo, Akira Inoue, et al.. (2015). Factors associated with a poor response to gefitinib in the NEJ002 study: Smoking and the L858R mutation. Lung Cancer. 88(2). 181–186.
7.
Morikawa, Naoto, Yuji Minegishi, Akira Inoue, et al.. (2015). First-line gefitinib for elderly patients with advanced NSCLC harboring EGFR mutations. A combined analysis of North-East Japan Study Group studies. Expert Opinion on Pharmacotherapy. 16(4). 465–472.
8.
Watanabe, Satoshi, Yuji Minegishi, Hirohisa Yoshizawa, et al.. (2014). Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q. Journal of Thoracic Oncology. 9(2). 189–194.
9.
Kawashima, Yosuke, Akira Inoue, Shunichi Sugawara, et al.. (2014). Phase II study of amrubicin combined with carboplatin for refractory relapsed small-cell lung cancer: North Japan Lung Cancer Group Trial 0802. Respiratory Investigation. 52(3). 190–194.
10.
Inoue, Akira, Shunichi Sugawara, Masao Harada, et al.. (2014). Phase II Study of Amrubicin Combined with Carboplatin for Thymic Carcinoma and Invasive Thymoma: North Japan Lung Cancer Group Study 0803. Journal of Thoracic Oncology. 9(12). 1805–1809.
11.
Seto, Takashi, Katsuyuki Kiura, Makoto Nishio, et al.. (2013). CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study. The Lancet Oncology. 14(7). 590–598.
12.
Kubota, Kaoru, Toyoaki Hida, Satoshi Ishikura, et al.. (2012). Randomized phase III study comparing etoposide and cisplatin (EP) with irinotecan and cisplatin (IP) following EP plus concurrent accelerated hyperfractionated thoracic radiotherapy (EP/AHTRT) for the treatment of limited-stage small-cell lung cancer (LD-SCLC): JCOG0202.. Journal of Clinical Oncology. 30(15_suppl). 7028–7028.
13.
Maemondo, Makoto, Yuji Minegishi, Akira Inoue, et al.. (2012). First-Line Gefitinib in Patients Aged 75 or Older With Advanced Non–Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Mutations: NEJ 003 Study. Journal of Thoracic Oncology. 7(9). 1417–1422.
14.
Akie, Kenji, Satoshi Oizumi, Shigeaki Ogura, et al.. (2011). Phase II Study of Irinotecan plus S-1 Combination for Previously Untreated Advanced Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0601. Oncology. 81(2). 84–90.
15.
Yokouchi, Hiroshi, Koichi Yamazaki, Ichiro Kinoshita, et al.. (2007). Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer. BMC Cancer. 7(1). 51–51.
16.
Furusyo, Norihiro, Iwao Ariyama, Yong Chong, et al.. (2002). A patient with primary human immunodeficiency virus infection for whom highly active antiretroviral therapy was successful. Journal of Infection and Chemotherapy. 8(4). 361–364.
17.
Dosaka‐Akita, Hirotoshi, et al.. (1995). Prognostic significance of p53 andras p21 expression in nonsmall cell lung cancer. Cancer. 76(12). 2457–2463.
18.
Harada, Masao, Hirotoshi Dosaka‐Akita, Hiroshi Miyamoto, Noboru Kuzumaki, & Yoshikazu Kawakami. (1992). Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer. Cancer. 69(1). 72–77.
19.
Kubota, Isao, Yoshihiko Watanabe, Hitomi Suzuki, et al.. (1981). TREADMILL STRESS TEST USING BODY SURFACE MAPPING : THE CLINICAL SIGNIFICANCE OF ST-DEPRESSION : Mapping : FREE COMMUNICATIONS (Abstract) : 45 Annual Scientific Meeting, Japanese Circulation Society. Japanese Circulation Journal-english Edition. 45(8). 917–918.
20.
Takei, Yo‐ichi, Masao Harada, & Katsuyoshi Mizuno. (1977). Pigmented Paravenous Retinochoroidal Atrophy. Japanese Journal of Ophthalmology. 21(3). 311–317.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Katsuhiro Masago Breakdown of academic impact, for papers by Alejandro Navarro Breakdown of academic impact, for papers by G. Robinet Breakdown of academic impact, for papers by Motoko Tachihara Breakdown of academic impact, for papers by Maximilian J. Hochmair Breakdown of academic impact, for papers by Panos Fidias Breakdown of academic impact, for papers by Giulia Pasello Breakdown of academic impact, for papers by Francesco Facchinetti Breakdown of academic impact, for papers by Saiama N. Waqar Breakdown of academic impact, for papers by See Phan